News stories about AC Immune (NASDAQ:ACIU) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. AC Immune earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.9968473452542 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
NASDAQ ACIU traded down $0.08 on Tuesday, reaching $9.52. 22,000 shares of the company’s stock traded hands, compared to its average volume of 46,984. The company has a market capitalization of $540.08 million, a PE ratio of -31.73 and a beta of 2.18. AC Immune has a fifty-two week low of $6.03 and a fifty-two week high of $13.91.
AC Immune (NASDAQ:ACIU) last posted its earnings results on Wednesday, May 2nd. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.03. The company had revenue of $1.58 million during the quarter, compared to the consensus estimate of $2.18 million. AC Immune had a negative net margin of 147.54% and a negative return on equity of 25.06%. equities analysts predict that AC Immune will post -1.05 earnings per share for the current year.
ACIU has been the subject of a number of research reports. Zacks Investment Research downgraded shares of AC Immune from a “hold” rating to a “sell” rating in a research report on Thursday, April 5th. Credit Suisse Group set a $14.00 target price on shares of AC Immune and gave the company a “hold” rating in a research report on Thursday, May 3rd. BidaskClub downgraded shares of AC Immune from a “hold” rating to a “sell” rating in a research report on Friday, March 2nd. ValuEngine upgraded shares of AC Immune from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Finally, HC Wainwright initiated coverage on shares of AC Immune in a research report on Thursday, April 5th. They set a “buy” rating and a $18.00 target price for the company. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $13.75.
About AC Immune
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.